Suzhou Bangqi Biotechnology Co., Ltd.（translated from company’s Chinese name） completed tens of millions of yuan in Series A financing, laying out the field of self-free & allergy diagnosis

Recently, Suzhou Bangqi Biotechnology announced that it has completed tens of millions CNY in Series A financing. This round of financing was led by Honest Capital and followed by Relay Fund. The raised funds are used for product pipeline expansion, medical device registration application, and rapid project advancement.

Autoimmune diseases are difficult to diagnose and treat. They are listed as ten major diseases in China. After cardiovascular and cerebrovascular diseases and tumors, autoimmune diseases are listed by WHO as the third largest killer threatening human health. There are about 50 million autoimmune patients in China, and only 17.414 million suffer from rheumatoid arthritis, ankylosing spondylitis, psoriasis and systemic lupus erythematosus.

With the process of urbanization, the incidence of allergic diseases is increasing year by year, and it is listed by the World Health Organization as one of the three major diseases to be studied and prevented in the 21st century. There are about 300 million allergic disease patients in China, and the number of asthmatics (Asthma) among people aged 20 and above alone reaches 45.7 million.

The base of autoimmune & allergy patients is large, few manufacturers in China participate, the diagnosis technology is relatively backward, and the diagnosis rate is low. As the country vigorously promotes the establishment of rheumatology and immunization departments in major hospitals in terms of policies, the autoimmune & allergy market will show a rapid growth trend, with great growth potential and rapid growth. At the same time, the overall domestic substitution trend of medical devices will also bring broad growth space to domestic manufacturers.

Suzhou Bangqi Biotechnology was established in 2020, focus on autoimmune and allergy. Its products cover instruments and reagents.